TY - JOUR
T1 - H_pe for mHealth
T2 - More " y" or " o" on the horizon?
AU - Labrique, Alain
AU - Vasudevan, Lavanya
AU - Chang, Larry William
AU - Mehl, Garrett
N1 - Funding Information:
This ‘call for evidence’ has been echoed by many groups, including the World Health Organization, culminating in 2011 by a global statement endorsed by leading research and implementation agencies – the Bellagio Call to Action on Global eHealth Evaluation [4] . This reflected an effort to acknowledge the criticized “hype” associated with innovation in the mHealth space, and to affirm, across a wide range of stakeholders, the critical role that evidence plays in promoting these strategies. The Bellagio statement calls for rigorous evaluation “to generate evidence and promote the appropriate integration and use of technologies…to improve health and reduce health inequalities” [4] . Other groups, such as the Robert Wood Johnson Foundation, McKesson Foundation, the National Science Foundation and the Office of Behavioral and Social Sciences Research at NIH have begun to invest in rigorous testing and evaluation of mHealth strategies; and through the UN Innovations Working Group, the Norwegian Agency for Development Cooperation (NORAD) supports mHealth implementation research. Discussions catalyzed by these stakeholders have resulted in calls for the development of robust but novel research designs for analyzing data obtained from mHealth applications [5] . Mechanisms to help policymakers assess the weight of evidence in mHealth have also been identified as a gap in this space, requiring the adaptation of existing systems such as the GRADE framework or the CONSORT-EHEALTH checklist [6,7] .
PY - 2013/5
Y1 - 2013/5
N2 - Objective: Efforts in the domain of mobile health, or mHealth, have been criticized for the unfettered proliferation of pilots and a lack of a rigorous evidence base to support these strategies. In this letter, we present the response of a group of researchers in the mHealth community to the recent calls for evidence issued by global health and funding agencies. We support our conclusions through a summary of the numerous ongoing mHealth studies listed in the US federal clinical trial registry. Methods: We conducted a search on the US federal clinicaltrials.gov database using the keywords "mHealth", "mobile" or "cell AND phone" to obtain 1678 results of studies. We manually inspected each result to check if it fit the purview of an mHealth study. Studies that were terminated or withdrawn prior to submission were excluded. Results: We identified 215 unique mHealth studies that were registered in the clinicaltrials.gov database, of which 8.4% (n = 18) were observational in nature while the remaining 91.6% (n = 197) were interventional. Of the 215 studies, 81.8% (n = 176) studies used a classical randomized trial design and 40 new studies were added to the database between May and November 2012 alone. Based on these results, we posit that the field is entering a new 'era' where a body of rigorous evaluation of mHealth strategies is rapidly accumulating. Conclusions: The transition into an era of evidence-based mHealth supports our position that innovation in this domain can be evaluated with the same rigor as other public health strategies, attenuating some of the hype previously associated with mHealth.
AB - Objective: Efforts in the domain of mobile health, or mHealth, have been criticized for the unfettered proliferation of pilots and a lack of a rigorous evidence base to support these strategies. In this letter, we present the response of a group of researchers in the mHealth community to the recent calls for evidence issued by global health and funding agencies. We support our conclusions through a summary of the numerous ongoing mHealth studies listed in the US federal clinical trial registry. Methods: We conducted a search on the US federal clinicaltrials.gov database using the keywords "mHealth", "mobile" or "cell AND phone" to obtain 1678 results of studies. We manually inspected each result to check if it fit the purview of an mHealth study. Studies that were terminated or withdrawn prior to submission were excluded. Results: We identified 215 unique mHealth studies that were registered in the clinicaltrials.gov database, of which 8.4% (n = 18) were observational in nature while the remaining 91.6% (n = 197) were interventional. Of the 215 studies, 81.8% (n = 176) studies used a classical randomized trial design and 40 new studies were added to the database between May and November 2012 alone. Based on these results, we posit that the field is entering a new 'era' where a body of rigorous evaluation of mHealth strategies is rapidly accumulating. Conclusions: The transition into an era of evidence-based mHealth supports our position that innovation in this domain can be evaluated with the same rigor as other public health strategies, attenuating some of the hype previously associated with mHealth.
KW - Evaluation
KW - Evidence
KW - mHealth
UR - http://www.scopus.com/inward/record.url?scp=84876972299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876972299&partnerID=8YFLogxK
U2 - 10.1016/j.ijmedinf.2012.11.016
DO - 10.1016/j.ijmedinf.2012.11.016
M3 - Letter
C2 - 23279850
AN - SCOPUS:84876972299
SN - 1386-5056
VL - 82
SP - 467
EP - 469
JO - International Journal of Medical Informatics
JF - International Journal of Medical Informatics
IS - 5
ER -